Why have it done in China specifically?

China offers this advanced combination therapy at a total cost of approximately $2,800, significantly lower than in Western countries. Chinese ophthalmology centers are equipped with state-of-the-art laser and imaging technology, and retinal specialists perform high volumes of these procedures, ensuring extensive clinical experience. Additionally, conbercept is a domestically developed anti-VEGF agent with proven efficacy, providing a cost-effective alternative to imported biologics.